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HEREAS	cellular	senescence	is	now	well	recognized	
as	a	potent	tumor	suppressor	mechanism,	its	role	in	
aging	is	still	controversial	(1).	Nevertheless,	cellular	senes-
cence	has	been	widely	used	as	a	model	system	to	study	ag-
ing	of	various	human	tissues.	Thus,	senescent	cells	have	
been	described	in	mitotic	tissue	of	aging	rodents	(2),	nonhu-
man	primates	(3),	as	well	as	in	human	aged	tissues,	such	as	
the	skin	(4,5),	the	vascular	system	(6),	and	the	kidney	(7).	
The	premature	appearance	of	senescent	cells	in	the	vascular	
endothelium	 has	 been	 associated	 with	 the	 onset	 of	 age-	
associated	cardiovascular	diseases,	such	as	arteriosclerosis	
(8).	Furthermore,	apoptosis	and	senescence	are	considered	
important	factors	contributing	to	vascular	dysfunction	and	
pathology	(9).
Senescent	cells	can	also	have	detrimental	effects	on	their	
microenvironment	and	neighboring	cells	due	to	the	dysregula-
tion	of	their	metabolism	and	changes	in	the	secretome	(for	re-
view,	see	[10]).	The	secretome	of	senescent	cells,	referred	to	 	
as	the	senescence-associated	secretory	phenotype	(11)	or	the	 	
senescence-messaging	secretome	(12),	is	complex	and,	besides	
cytokines	and	chemokines	(13),	includes	other	factors	that	are	
involved	in	senescence-associated	proliferation	arrest,	such	as	
insulin-like	growth	factors	and	insulin-like	growth	factor	bind-
ing	proteins	(14,15),	and	extracellular	matrix	remodeling,	such	
as	matrix	metalloproteinase-1	and	-3	(16).	Cytokines	of	the	
senescence-associated	secretory	phenotype,	like	interleukin	
(IL)-1	or	members	of	the	tumor	necrosis	factor	(TNF)	
superfamily,	are	known	regulators	of	nuclear	factor	kappa	 	
B	(17),	consistent	with	an	emerging	role	for	nuclear	fac-
tor	kappa	B	in	the	regulation	of	cellular	senescence	(18).
In	1997,	a	new	member	of	the	TNF-ligand	superfamily	
was	discovered	by	searching	a	cDNA	database	(19).	After	
preliminary	 experiments	 with	 a	 partial	 cDNA,	 which	
blocked	the	proliferation	of	endothelial	cells,	the	novel	TNF	
ligand	 was	 named	 vascular	 endothelial	 growth	 inhibitor	
(VEGI)	 (20).	 The	 full-length	 gene	 product	 (251	 amino	 	
acids)	was	referred	to	as	TNF-like	cytokine	1A	(TL1A),	
VEGI-251	(21),	or,	most	recently,	as	TNF	(ligand)	super-
family,	member	15	(TNFSF15)	(22).	For	convenience,	the	
gene	is	referred	to	as	TL1A	throughout	this	article.	Two	iso-
forms	of	TL1A,	referred	to	as	VEGI-174	and	VEGI-192,	
supposed	to	be	produced	by	alternative	splicing,	were	also	
described	(23–25);	however,	the	physiological	relevance	of	
these	isoforms	remained	largely	unclear	(see	subsequently).
TL1A	is	a	unique	TNF	ligand	because	it	is	predominantly	
expressed	in	endothelial	cells	(20).	To	a	minor	extent,	TL1A	
is	 also	 expressed	 in	 tissue	 macrophages,	 lamina	 propria	 	
T	cells	and	plasma	cells,	FcgR-activated	peripheral	blood	
mononuclear	 cells	 (PBMC),	 and	 monocyte-derived	 den-
dritic	cells	(26–29).	TL1A	is	the	only	known	ligand	for	the	
death	receptor	DR3	(TNFRSF12)	(21).	DR3	was	shown	to	
be	 primarily	 expressed	 in	 activated	 lymphocytes	 (30,31)	
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and	to	a	minor	extent	in	natural	killer	(NK)	cells,	macro-
phages,	and	endothelial	cells,	such	as	human	umbilical	vein	
endothelial	cells	(HUVEC)	(27,32–34).	TL1A	is	also	a	li-
gand	for	decoy	receptor	3	(DcR3/	TNFRSF6B)	(21).	DcR3	
messenger	RNA	(mRNA)	is	expressed	in	several	human	tis-
sues	like	spleen,	lung,	and	the	gastrointestinal	tract,	as	well	as	
in	HUVEC	(35).	TL1A	was	shown	to	be	involved	in	several	
inflammatory	 diseases,	 such	 as	 renal	 inflammation	 (25),	
Crohn’s	 disease	 (36),	 inflammatory	 bowel	 disease	 (26),	
rheumatoid	arthritis	(37,38),	and	autoimmune	diseases	(39).	
Recent	research	on	DR3-	and	TL1A-knockout	mice	con-
firmed	an	important	role	of	TL1A/DR3	in	autoimmune	and	
inflammatory	diseases	(40,41).	An	involvement	of	TL1A	
and	DR3	in	atherosclerosis	was	also	shown	(27,42,43).	This	
is	reasonable	because	the	development	of	atherosclerosis	
has	 an	 autoimmune	 component	 and	 is	 considered	 as	 an	 	
inflammatory	disease	(44).
Although	 research	 on	TL1A	 is	 already	 in	 progress	 for	
more	than	10	years,	studies	on	the	consequences	of	ectopic	
overexpression	of	TL1A	cDNA	in	human	cells	are	sparse	and	
conflicting	(21,23).	In	fact,	the	main	focus	of	research	until	
today	was	the	exploration	of	the	antiangiogenic,	apoptosis	
stimulating,	and	immunomodulatory	functions	of	recombi-
nant	fragments	of	TL1A,	most	of	which	have	no	defined	
counterpart	in	vivo.	In	a	limited	RNA	profiling	study	com-
paring	young	and	senescent	HUVEC,	we	have	found	previ-
ously	 that	 TL1A	 expression	 was	 increased	 in	 senescent	
HUVEC	(45);	however,	no	in-depth	analysis	or	functional	
studies	were	performed.	This	is	the	focus	of	the	present	study.
Methods
Chemicals to Manipulate Ectodomain Shedding
The	tumor	necrosis	factor-a	protease	inhibitor-1	(TAPI-1)	
is	an	ADAM17/10	(TACE)	inhibitor	(Cat.	No.	579051;	
Calbiochem	Merck	Chemicals,	Nottingham,	UK).	TAPI-1	
was	dissolved	in	DMSO	to	a	final	concentration	of	10	mM.	
The	end	concentration	of	TAPI-1	in	the	culture	medium	was	
10	or	20	mM.	Stock	solutions	were	stored	at	−20°C.	Phorbol-
12-myristat-13-acetate	(PMA)	(Sigma-Aldrich,	Vienna,	Austria)	
was	dissolved	in	DMSO	to	a	stock	concentration	of	10	mg/mL	
and	stored	at	−20°C.	To	induce	ectodomain	shedding	activity	
10–50	ng/mL	PMA	in	culture	medium	was	used.	H2O2	(Sigma	
H1009)	was	stored	at	4°C	as	a	30%	solution,	and	1–5	mM	
H2O2	was	used	in	experiments.
Cell Culture
The	growth	and	maintenance	of	the	293FT	cell	line	was	
performed	like	described	in	Invitrogen’s	(Lofer,	Austria)	user	
manual	(Cat.	No.	R700-07,	WFGE08S).	Circulating	endothe-
lial	 progenitor	 cells	 (CEP)	 were	 isolated	 from	 peripheral	
blood	of	healthy	donors	with	written	consent	and	maintained	
according	to	the	methods	described	in	(46).	Cells	were	propa-
gated	in	Endothelial	Cell	Growth	Medium-2	(EGM-2,	CC-
3162;	Lonza,	Verviers,	Belgium).	HUVEC	were	isolated	and	
maintained	according	to	the	methods	described	in	(47).	Cells	
were	propagated	in	Endothelial	Cell	Growth	Medium	(EGM,	
CC-3124;	Lonza).	U-2OS	cells	were	obtained	from	ATCC	and	
propagated	in	Dulbecco’s	modified	Eagle’s	medium	(Sigma	
D5546)	supplemented	with	10%	heat-inactivated	fetal	bovine	
serum,	4	mM	l-glutamine	(Gibco	Invitrogen,	Lofer,	Austria),	
and	1%	penicillin	streptomycin	(Gibco).	For	determining	cell	
number	and	viability,	the	CASY	Model	DT	was	used	from	In-
novatis	AG	(Reutlingen,	Germany).
Cell Proliferation and Apoptosis
Cell	 proliferation	 was	 assayed	 using	 the	 5-bromo-2′-
deoxy-uridine	 labeling	 and	 detection	 kit	 I	 (Cat.	 No.	
11296736001;	Roche,	Vienna,	Austria)	as	described	in	the	
manufacturer’s	manual.	The	cell	nuclei	were	counterstained	
with	4-6-diamidino-2-phenylindole	(2	ng/mL)	in	DABCO	
mounting	medium.	Bound	anti-bromodeoxyuridine	mono-
clonal	antibody	was	visualized	by	immunofluorescence	mi-
croscopy,	and	the	percentage	of	bromodeoxyuridine-stained	
nuclei	was	calculated.
For	 detection	 of	 apoptosis,	 the	 cells	 were	 detached,	
washed	once	with	phosphate-buffered	saline	(PBS),	and	in-
cubated	with	100	mL	Annexin	V	buffer	containing	10	mM	
HEPES,	140	mM	NaCl,	and	2.5	mM	CaCl2	(pH	7.4)	and	
3	mL	of	Annexin	V-fluoresceinisothiocyanate	(Pharmingen	
BD	Biosciences,	Heidelberg,	Germany)	for	15	minutes	at	
room	temperature.	After	the	incubation,	300	mL	of	Annexin	
V	buffer	was	added	and	the	cell	suspension	was	measured	
by	fluorescence	activated	cell	sorting	(FACS).
Tube Formation Assay
The	tube	formation	assay	for	endothelial	cells	determines	
their	ability	to	form	a	capillary-like	tubular	structure	on	a	
special	extracellular	matrix	called	Matrigel	basement	mem-
brane	(basement	membrane	matrix,	growth	factor	reduced	
matrigel,	Cat.	No.	356231;	BD	Biosciences).	This	assay	
served	an	in	vitro	angiogenesis	assay.	Matrigel	stored	at	
−20°C	 was	 thawed	 at	 4°C.	 Two	 hundred	 microliters	 of	
Matrigel	was	transferred	in	each	well	of	a	24-well	plate	on	
ice	using	cold	pipet	tips.	The	plate	was	incubated	at	37°C	
for	30	minutes,	and	20,000	up	to	40,000	cells	were	seeded	
with	300	mL	medium.	After	12	hours	of	incubation,	branch-
ing	points	of	the	tubes	were	counted.
Lentiviral Overexpression and Knockdown of TL1A
As	a	transfer	vector	for	overexpression	of	TL1A,	the	len-
tiviral	pLenti6/UbC/V5-DEST	Gateway	vector	(Invitrogen)	
was	used.	Cloning	procedure	involved	the	TOPO	cloning	of	
TL1A	into	pENTR/D-TOPO	thereby	the	V5	Tag	was	re-
moved	by	introduction	of	a	stop	codon	after	the	coding	se-
quence	 of	TL1A	 (GenBank	 NM_005118).	The	 resulting	
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into	pLenti6/UbC/V5-DEST	by	recombination	to	generate	
the	 transfer	 vector	 pLenti6/UbC/TL1A	 (see	 Invitrogen’s	 	
ViraPower Lentiviral Expression System	manual	for	further	
details).	Control	vector	(Mock)	was	generated	by	removing	
the	TL1A	coding	sequence	from	pLenti6/UbC/TL1A	with	
EcoRV	and	religation	of	the	lentiviral	backbone.	As	a	trans-
fer	vector	for	knockdown	of	TL1A,	we	used	the	lentiviral	
pLKO.1-TRC	 short-hairpin	 vector	 from	 Addgene/Open	
Biosystems	(Epsom,	UK).	Following	sequences	within	the	
TL1A,	mRNAs	were	chosen	as	target:	pLKO1	within	the	 	
3′	 noncoding	 region	 of	 TL1A	 (5′-GAGGAGACTGAGT-
GATTAA-3′)	 and	 pLKO99	 within	 the	 coding	 region	
(5′-GCCATGTTCTCC	 TTGCAAGAA-3′).	The	short	hair-
pin	RNA	for	pLKO1	was	designed	using	the	Dharmacon	
siDESIGN	 center	 (for	 cloning	 procedure,	 refer	 to	 the	
pLKO.1-TRC	 Cloning	 Vector	 manual	 from	 Addgene).	
Transfer	vector	pLKO99	was	obtained	from	Open	Biosys-
tems.	As	a	control	the	pLKO.1-TRC	control	vector	(Add-
gene	 plasmid	 10879)	 was	 used.	 For	 packaging	 of	 the	
lentivirus	in	293FT	cells	(Invitrogen),	the	corresponding	
overexpression	or	knockdown	transfer	vector	was	used	to-
gether	with	psPAX2	(Addgene	plasmid	12260)	and	pMD2.G	
(Addgene	plasmid	12259).	293FT	cells	were	cultivated	in	
T75	flasks	to	90%	confluence	and	transfected	with	a	mix-
ture	of	3	mg	of	the	transfer	vector,	7.5	mg	psPAX2	and	2.5	mg	
pMD2.G	using	Lipofectamine	2000	(Invitrogen).	On	the	
next	day,	the	supernatant	was	exchanged	with	10	mL	of	
fresh	293FT	growth	medium.	The	supernatant	was	then	har-
vested	48	hours	later,	centrifuged	at	400g	to	get	rid	of	cell	
debris,	filtered	through	0.45-mm	filter	(Millipore,	Vienna,	
Austria),	and	stored	at	−80°C.	The	titer	of	lentiviral	super-
natant	was	determined	by	limiting	dilution	on	50,000	seeded	
U-2OS	in	six-well	plates	with	8	mg/mL	hexadimethrine	bro-
mide	 (polybrene)	 as	 transduction	 enhancer.	 To	 produce	 	
4	mg/mL	stock	solution,	hexadimethrine	bromide	(Cat.	No.	
10,768-9;	Sigma-Aldrich)	was	diluted	in	sterile	water	and	
filtered	trough	a	0.22-mm	sterile	filter.	To	avoid	freeze/
thaw	cycles,	only	small	aliquots	were	stored	at	−20°C.	To	
select	for	transduced	cells,	10	mg/mL	blasticidin	for	overex-
pression	and	200	ng/mL	puromycin	for	knockdown	virus	
was	added	1	day	after	transduction.	After	6	days	of	selec-
tion,	the	colonies	were	stained	using	crystal	violet	(1%	in	
10%	 ethanol).	 In	 general,	 titers	 for	 overexpression	 virus	
were	about	1	×	106	transforming	units	per	milliliter	(TU/
mL)	and	for	knockdown	virus	5	×	106	TU/mL.	For	trans-
duction	of	HUVEC	and	CEP,	a	multiplicity	of	infection	of	
4–8	was	used	together	with	8	mg/mL	hexadimethrine	bro-
mide.	Four	multiplicity	of	infection	was	sufficient	to	trans-
duce	100%	of	seeded	HUVEC	as	assessed	by	fluorescence	
microscopy	of	green	fluorescent	protein–transduced	cells.
Reverse Transcriptase–Polymerase Chain Reaction
For	 RT-PCR,	 the	 mRNA	 of	 cells	 was	 isolated	 using	 	
the	RNeasy	mini	kit	(Cat.	No.	74104;	Qiagen,	Vienna,	
Austria)	 and	 reverse	 transcribed	 into	 cDNA	 using	 the	
transcriptor	 first-strand	 cDNA	 synthesis	 kit	 (Cat.	 No.	
04896866001;	Roche),	following	procedure	A	of	the	pro-
vided	 protocol	 with	 anchored	 oligo(dT)18	 primers.	 The	
cDNA	was	then	used	as	a	template	for	a	standard	PCR	fol-
lowed	by	standard	agarose	gel	analysis.	Following	isoform-
specific	primer	pairs	were	used	for	the	detection	of	TL1A	
(VEGI-251)	 and	 its	 isoforms:	 TL1A	 (VEGI-251)	 (fw	
5′-TGCAGGACTCACCACATA-3′	 rev	 5′-CTTGGCT-
TATCTCCGTCT-3′);	VEGI-174	 (fw	 5′-GCAAGTCTA-
CAGTTTCCC-3′	rev	5′-TTCGGTTCTTGGTGAAGG-3′);	
VEGI-192	 (fw	 5′-TTCAGTCACCCTTTGTCTC-3′	 rev	
5′-AGGCCTAGTTCATGTTCC-3′).
Real-Time-quantitative-PCR
Isolation	 of	 mRNA	 and	 cDNA	 generation	 was	 per-
formed	like	described	previously.	To	quantify	the	amount	
of	 cDNA	 template,	 a	 real-time-quantitative-PCR	 (RTq-
PCR)	was	established	using	isoform-specific	primer	pairs	
(see	previously)	and	SYBR.	For	relative	quantification,	an	
efficiency	 	 -corrected	calculation	model	of	the	D-D	CT	method	
was	used	(48).	For	normalization	of	the	isoform-specific	
RTq-PCR,	levels	of	b-2	microglobulin	were	quantified	in	
parallel.
Microarray Hybridization and Evaluation
To	prepare	RNA	for	cDNA	microarray	hybridization,	the	
RNeasy	Mini	Kit	(Cat.	No.	74104;	Qiagen)	was	used.	For	hy-
bridization,	the	human	genome	U133	plus	2.0	arrays	from	 	
Affymetrix	(High	Wycombe,	UK)	were	used.	The	microarrays	
were	hybridized	and	analyzed	by	the	microarray	facility	
(Microarray	 Facility	 Tübingen,	 Tübingen,	 Germany,	
www.microarray-facility.com).	A	compact	disc	containing	
the	image	analysis	of	the	microarray	experiment	with	the	
raw	data	was	provided	by	the	Microarray	Facility.	These	
raw	data	sets	were	prepared	for	analysis	using	CARMAweb	
(Institute	 for	 Genomics	 and	 Bioinformatics,	 Graz,	Austria,	
https://carmaweb.genome.tugraz.at/carma	 )	(	 49	 ).	For	normali- )	(49).	For	normali-
zation,	the	algorithm	“gcrma”	was	used.
Deglycosylation of TL1A
In	order	to	detect	N-	and	O-linked	oligosaccharides	in	
TL1A,	the	glycoprotein	deglycosylation	kit	from	Calbio-
chem	Merck	Chemicals	(Cat.	No.	362280)	was	used.	Ac-
cording	 to	 the	 manufacturer’s	 manual,	 cell	 lysate	 or	
supernatant	 of	 TL1A	 overexpressing	 U-2OS	 together	
with	supplied	reaction	buffer	and	denaturation	solution	
was	heated	at	100°C	for	5	minutes.	After	cooling	to	room	
temperature,	Triton	X-100	detergent	solution	was	added.	
N-glycosidase	F	was	added	to	cleave	N-glycans.	To	cleave	
N-	 and	 O-linked	 oligosaccharides,	 N-glycosidase	 F,	 a2-
3,6,8,9-neuraminidase,	endo-a-N-acetylgalactosaminidase,	
b-1,4-galactosidase,	and	b-N-acetylglucosaminidase	were	MÜCK ET AL. 1168
added	sequentially.	Reactions	were	incubated	for	3	hours	at	
37°C.	The	shift	in	molecular	mass	by	deglycosylation	was	
analyzed	by	sodium	dodecyl	sulfate–polyacrylamide	gel	elec-
trophoresis	followed	by	Western	blotting.
Western Blot of Cell Lysates and Supernatants
TL1A-transfected	U-2OS	cells	were	grown	in	six-well	
plates	 to	 about	 80%–100%	 confluency.	 To	 produce	 cell	 	
supernatants,	the	cells	were	washed	three	times	with	PBS	and	
incubated	with	serum-free	Dulbecco’s	modified	Eagle’s	me-
dium	for	5	hours	to	get	rid	of	the	residual	fetal	bovine	serum.	
Then,	the	medium	was	exchanged	with	800	mL	per	well	
fresh	serum-free	Dulbecco’s	modified	Eagle’s	medium	con-
taining	1%	penicillin	streptomycin	and	4	mM	l-glutamine.	
Depending	on	the	experiment	after	2–48	hours,	the	superna-
tants	were	harvested,	centrifuged	at	1000g	for	5	minutes	to	
get	rid	of	cell	debris	and	filtered	through	0.45-mm	filter	
(Millipore).	If	the	concentration	of	TL1A	in	the	supernatant	
was	too	low	to	detect	by	Western	blot,	it	was	concentrated	
about	eightfold	by	speed-vac	evaporation.	The	resulting	su-
pernatant	was	mixed	with	sodium	dodecyl	sulfate	protein	
buffer	containing	300	mM	Tris–HCl	pH	6.8,	500	mM	di-
thiothreitol,	10%	sodium	dodecyl	sulfate,	0.5%	bromphenol	
blue,	and	50%	glycerin.	Lysis	buffer	contained	50	mM	Tris–
HCl,	150	mM	NaCl,	1%	NP-40,	0.1%	sodium	dodecyl	sul-
fate,	0.5%	Na-deoxycholate,	0.2	mM	phenylmethylsulfonyl	
fluoride,	1	mM	NaF,	10	mg/mL	aprotinin,	and	10	mg/mL	
leupeptin	(pH	7.5).	Cell	lysates	and	supernatants	were	as-
sayed	by	standard	Western	blot	protocol	using	primary	goat	
anti-human	 TL1A/TNFSF15	 antibody	 (Cat.	 No.	AF744;	
R&D	Systems,	Biomedica,	Vienna,	Austria)	and	mouse	
b-Tubulin	 antibody	 (Sigma).	 Horseradish	 peroxidase–
conjugated	secondary	antibodies	were	purchased	from	Dako,	
Vienna,	Austria.
AMAXA Electroporation
To	 introduce	 expression	 plasmids	 into	 HUVEC,	 the	
HUVEC	 nucleofector	 kit	 (Cat.	 No.	 VPB-1002)	 from	
AMAXA,	Lonza,	Verviers,	Belgium	was	used.	The	method	
was	 performed	 like	 described	 in	 the	 manufacturer’s	
protocol.
Staining for Senescence-Associated b-Galactosidase
The	senescent	status	was	verified	by	in	situ	staining	for	 	
senescence-associated	b-galactosidase	(SA-b-gal)	as	described	
(4).	Cells	were	grown	on	six-well	cell	culture	dishes,	washed	
three	times	with	PBS,	and	fixed	with	2%	formaldehyde,	0.2%	
glutaraldehyde	in	PBS	for	5	minutes.	After	another	washing	
step	with	PBS,	the	cells	were	incubated	with	b-galactosidase	
staining	solution	(150	mM	NaCl,	2	mM	MgCl,	2.5	mM	potas-
sium	ferricyanide,	5	mM	potassium	ferrocyanide,	40	mM	cit-
ric	acid,	12	mM	sodium	phosphate,	pH	6.0,	adding	1	mg/mL	
5-bromo-4-chloro-3-indolyl-b-D-galactoside	[X-gal]	directly	
before	staining	of	the	cells)	for	24	hours	at	37°C.	The	reaction	
was	stopped	by	washing	the	cells	with	PBS.
Expression and Purification of TL1A Fragments From 
Escherichia	coli
For	expression	of	recombinant	TL1A	in	Escherichia 
coli,	the	pET-3a	vector	from	Novagen	(Merck;	Cat.	No.	
69418-3)	was	used.	For	directional	cloning,	forward	prim-
ers	were	designed	that	harbor	an	NdeI	restriction	site	and	
reverse	primers	with	a	BamHI	site.	For	TL1AL72-L251,	the	
primer	 pair	 (fw	 5′-TATACATATGCTGCACTGGGAA-
CATGAACTA-3′)	 and	 (rev	 5′-TATAGGATCCCTATAG-
TAAGAAGGCTCCAAAGAAGGT-3′)	 was	 used.	 For	
TL1AV84-L251,	(fw	5′-TATACATATGGTTTATGCACCTCT-
TAGAGCAGA-3′)	 in	 combination	 with	 the	 above-men-
tioned	reverse	primer	was	used.	After	PCR	using	full-length	
TL1A	vector	as	a	template,	the	amplified	fragments	were	
cloned	into	the	NdeI	and	BamHI	site	of	the	pET-3a	vector.	
TL1A	insert	sequences	were	verified	by	DNA	sequencing.	
Note	that	in	the	resulting	recombinant	protein,	there	will	be	
a	methionine	at	the	beginning	of	the	TL1A	fragment	but	no	
T7	Tag.	For	recombinant	protein	expression,	the	BL21(DE3)	
(Novagen)	E coli	strain	was	transformed	with	the	respective	
TL1A	 overexpression	 constructs,	 selected	 on	 LB	 plates	
containing	100	mg/mL	ampicillin	and	25	mg/mL	chloram-
phenicol	and	incubated	at	37°C.	Twenty	milliliters	of	LB	
medium	containing	antibiotics	as	described	previously	was	
inoculated	with	a	single	colony	from	the	LB	plate	and	incu-
bated	at	225	rpm/37°C	overnight.	Two	milliliters	of	the	over-
night	culture	was	centrifuged	and	resuspended	in	200	mL	of	
NZCYM	medium	(10	g	NZ	amine,	5	g	NaCl,	5	g	yeast	ex-
tract,	1	g	casamino	acids,	2	g	MgSO4×7H2O,	H2O	ad	950	
mL,	adjusted	to	pH	7.4	with	NaOH	and	filled	to	1000	mL)	
containing	ampicillin	(100	mg/mL)	and	chloramphenicol	(25	
mg/mL).	The	flask	was	incubated	at	225	rpm/37°C	until	the	
optical	density	at	600	nm	reached	0.5,	then	expression	was	
induced	by	adding	isopropyl-β-D-thiogalactopyranoside	to	a	
final	concentration	of	0.4	mM.	After	3	hours	of	shaking	at	225	
rpm/37°C,	bacteria	were	collected	by	centrifugation.	TL1A	
inclusion	bodies	were	isolated	by	lysis	of	the	bacterial	cells	
and	washing	thoroughly	using	inclusion	body	wash	buffer	
containing	25	mL	of	1	M	Tris–HCl	pH	8,	2	mL	of	0.5	M	
EDTA	pH	8,	0.35	mL/mL	b-mercaptoethanol,	25	mL	glyc-
erol,	0.25	g	sodium	deoxycholic	acid,	5	mL	igepal	CA-630	
(NP40)	filled	to	500	mL	with	H2O.	Inclusion	bodies	were	
solubilized	in	5	mL	of	8	M	urea	and	loaded	on	a	5	mL	
Ni2+	HiTrap	Chelating	HP	column	(GE	Healthcare,	Vienna,	
Austria)	that	was	equilibrated	with	8	M	urea.	TL1A	was	
slowly	refolded	on	the	column	with	a	linear	PBS	gradient	at	
a	flow	rate	of	1.5	mL/min	(40	bed	volumes).	Refolded	TL1A	
was	eluted	with	a	linear	imidazole	gradient	of	0–100	mM	 	
(10	bed	volumes)	at	a	flow	rate	of	1.5	mL/min.	Typically,	
the	fragments	eluted	at	about	37	mM	imidazole.	TL1A	 	
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PBS.	Concentration	of	TL1A	protein	was	assessed	by	mea-
surement	at	optical	density	of	280	nm.
Treatment and Analysis of PBMC
Peripheral	blood	samples	were	taken	from	three	healthy	
volunteers.	Informed	written	consent	was	obtained	from	all	
participants,	and	the	blood	collection	was	approved	by	the	
Ethics	 Committee	 of	 the	 Innsbruck	 Medical	 University.	
PBMC	were	purified	by	Ficoll-Hypaque	density	gradient	cen-
trifugation	(Amersham	Biosciences,	Vienna,	Austria).	About	
0.5	Mio	PBMC	were	incubated	in	48-well	plates	for	3	days	
with	IL-12	(10	ng/mL),	IL-18	(50	ng/mL),	IL-15	(50	ng/mL),	
and/or	TL1A	fragments	(50	mg/mL).	Brefeldin	A	(10	mg/mL)	
was	added	for	the	last	12	hours.	PBMC	were	washed	with	
PBS	and	stained	for	30	minutes	at	4–8°C	using	the	conjugated	
antibodies	anti-CD3	(APC-Cy7)	and	anti-CD8	(PerCP;	all	
BD	Biosciences).	After	washing	with	PBS,	PBMC	were	re-
suspended	in	Cytofix/Cytoperm	(BD	Biosciences)	for	20	mi-
nutes	at	4–8°C.	Cells	were	resuspended	in	Cytowash	buffer	
and	stained	with	anti-interferon	(IFN)-g	(fluoresceinisothio-
cyanate;	BD	Biosciences)	for	30	minutes	at	4–8°C.	After	a	
washing	step	with	Cytowash	buffer,	PBMC	were	resuspended	
in	PBS	and	analyzed	on	a	FACSCanto	II	flow	cytometer	and	
FACSDiva	Software	(BD	Biosciences).	NK	cells	were	de-
fined	within	the	lymphocyte	gate	as	CD3−CD8adim.
Results
TL1A Is the Main Isoform in HUVEC
In	 addition	 to	 canonical	 TL1A	 (VEGI-251),	 two	 iso-
forms,	 referred	 to	 as	VEGI-174	 and	VEGI-192,	 respec-
tively,	were	described	that	are	believed	to	be	generated	by	
differential	splicing	(23).	To	analyze	the	major	isoforms	in	
HUVEC,	 mRNA	 was	 isolated	 and	 reverse	 transcribed.	
About	250	ng	cDNA	was	then	used	to	perform	a	gradient	
RTq-PCR	with	isoform-specific	primers	and	35	amplifica-
tion	cycles	(Figure	1A).	A	faint	band	was	obtained	at	61°C	
annealing	temperature	for	the	VEGI-174	isoform,	whereas	
no	specific	band	(170	base	pairs)	was	detected	for	VEGI-
192.	With	a	distinct	band	of	the	expected	size	(147	base	
pairs),	VEGI-251	was	the	main	isoform	in	HUVEC.	There	
was	 no	 unspecific	 amplification	 or	 contamination	 of	 the	
PCR	reaction	(data	not	shown).
The	VEGI-174	mRNA	was	nearly	undetectable	in	HUVEC	
and	CEP,	consistent	with	previous	reports	that	VEGI-174	
might	be	a	cloning	artifact	(21).	To	address	this	point,	total	
RNA	from	human	placenta	was	reverse	transcribed,	whereby	
VEGI-174	cDNA	was	readily	detected	after	30	amplifica-
tion	 cycles	 (data	 not	 shown).	The	 identity	 of	VEGI-174	 	
was	verified	by	sequencing,	and	a	lentiviral	vector	for	the	
overexpression	 of	VEGI-174	 was	 generated.	 To	 monitor	
protein	products	resulting	from	the	expression	of	VEGI-174,	
U-2OS	cells	were	transiently	transfected	with	empty	vector	
(Mock)	or	pcDNA3.1	expressing	VEGI-174	and	analyzed	
by	Western	blotting	(Figure	1B,	left).	The	same	strategy	was	
applied	for	lentiviral	expression	of	VEGI-174	(Figure	1B,	
middle).	With	both	expression	methods,	a	relatively	weak	
protein	 band	 of	 an	 apparent	 molecular	 weight	 (MW)	 of	 	
22	 kDa	 was	 observed,	 which	 probably	 corresponds	 to	
VEGI-174.	When	the	supernatant	of	U-2OS	cells	overex-
pressing	 VEGI-174	 was	 examined	 by	 Western	 blot	 using	
TL1A	antibodies,	no	immunoreactive	fragment	was	detected,	
whereas	a	fragment	corresponding	to	TL1AL72-L251	was	readily	
detected	in	cellular	supernatants	after	overexpression	of	
Figure	1.	Abundance	of	tumor	necrosis	factor–like	cytokine	1A	(TL1A)	and	isoforms	in	human	umbilical	vein	endothelial	cells	(HUVEC)	and	expression	of	vascular	
endothelial	growth	inhibitor	(VEGI)-174	in	U-2OS.	(A)	cDNA	of	senescent	HUVEC	was	used	to	perform	a	gradient	RT-PCR	using	isoform-specific	primers	for	VEGI-174,	
VEGI-192,	and	TL1A	(VEGI-251).	The	annealing	temperature	gradient	reached	from	44.2	to	61°C.	After	35	amplification	cycles,	polymerase	chain	reaction	(PCR)	products	
were	subjected	to	agarose	gel	analysis.	The	expected	size	of	PCR	product	is	indicated	for	each	isoform.	(B)	U-2OS	cells	were	transiently	transfected	(left)	or	stably	transduced	
(middle)	with	a	eukaryotic	overexpression	vector	(pcDNA3)	or	a	lentiviral	vector	encoding	VEGI-174	cDNA,	respectively.	Empty	vector	(Mock)	was	used	as	a	control.	After	
6	days,	cell	extracts	were	analyzed	by	Western	blot	using	polyclonal	antibodies	specific	for	TL1A.	This	antibody	was	raised	against	the	C-terminal	part	of	TL1A	and	therefore	
should	also	be	able	to	detect	VEGI-174.	The	concentrated	supernatant	of	VEGI-174	and	TL1A	(VEGI-251)	transduced	cells	was	also	subjected	to	Western	blotting	(right).MÜCK ET AL. 1170
Figure	2.	 Ectodomain	shedding	of	transmembrane	tumor	necrosis	factor–like	cytokine	1A	(TL1A)	in	human	umbilical	vein	endothelial	cells	(HUVEC)	and	 	
U-2OS	cells.	(A)	HUVEC	were	transfected	with	TL1A	cDNA	or	empty	vector	(Mock)	by	AMAXA	electroporation,	immunostained	for	TL1A,	and	examined	by	
confocal	fluorescence	microscopy.	Nuclei	were	stained	with	TO-PRO	3	(right).	Expression	of	TL1A	was	verified	by	Western	blot	(left).	(B)	HUVEC	were	transfected	
with	either	empty	vector	(Mock)	or	a	TL1A	overexpression	vector	by	AMAXA	electroporation.	HUVEC	cell	extracts	and	supernatant	were	examined	by	Western	blot	
using	antibodies	specific	for	TL1A.	(C)	U-2OS	cells	were	transiently	transfected	with	TL1A	cDNA	and	Mock	using	Lipofectamine	2000.	After	antibiotic	selection	
for	transfected	cells,	they	were	seeded	at	a	density	of	3	×	105	per	well	in	a	six-well	plate.	Ten	micromolars	of	TAPI-1	and	the	equivalent	volume	of	DMSO	as	a	control	
were	added	as	indicated	and	incubated	for	24	hours.	Cell	extracts	and	speed-vac	concentrated	supernatants	were	examined	by	Western	blot	using	anti-TL1A	antibody.	
(D)	U-2OS	cells	were	treated	for	2	hours	with	50	ng/mL	phorbol-12-myristat-13-acetate	(PMA)	and	5	mM	H2O2,	as	indicated.	Micrographs	of	treated	cells	are	shown.	
(E	and	F)	U-2OS	cells	were	transfected	with	TL1A	cDNA	and	seeded	as	described	previously.	Cells	were	either	untreated	(NT)	or	treated	with	increasing	concentra-
tions	of	PMA	(E)	or	H2O2	(F)	in	the	presence	or	absence	of	TAPI-1	(20	mM),	as	indicated.	After	2	hours,	supernatants	were	harvested,	concentrated	by	speed-vac	
evaporation,	and	subjected	to	Western	blot	analysis.	(G)	Supernatant	of	U-2OS	cells	overexpressing	TL1A	was	concentrated	via	speed-vac	evaporation	and	treated	
with	the	indicated	enzymes	to	remove	all	N-	and	O-linked	oligosaccharides.	The	enzymes	were	added	sequentially,	in	a	cumulative	manner,	so	that	in	the	end	all	five	
enzymes	are	added	to	the	reaction	(from	left	to	right	on	the	indicated	Western	blot).	TL1A	fragments	were	separated	on	a	large	sodium	dodecyl	sulfate–polyacrylamide	
gel	electrophoresis	for	higher	resolution	and	analyzed	by	Western	blot	using	anti-TL1A	antibody. DIFFERENTIAL ECTODOMAIN SHEDDING OF TL1A 1171
TL1A/VEGI-251	(Figure	1B,	right).	Based	on	these	find-
ings,	VEGI-174	was	not	further	investigated.
Transmembrane Location and Ectodomain Shedding  
of TL1A
To	determine	the	subcellular	localization	of	TL1A	in	en-
dothelial	 cells,	 HUVEC	 were	 transiently	 transfected	 by	
AMAXA	 with	 a	 TL1A	 expression	 vector	 (pcDNA3.1/
TL1A).	Expression	of	TL1A	was	verified	by	Western	blot	
(Figure	 2A,	 left).	 Subcellular	 localization	 of	 TL1A	 was	
probed	by	indirect	immunofluorescence	using	two	fixation	
methods	 (methanol/acetone	 and	 paraformaldehyde).	 Both	
fixation	methods	revealed	the	accumulation	of	TL1A	at	the	
plasma	membrane,	with	additional	staining	of	a	perinuclear	
structure,	presumably	the	Golgi	apparatus	(Figure	2A,	right).	
It	is	known	that	the	extracellular	part	of	some	transmem-
brane	proteins,	in	particular	the	ligands	of	the	TNF	family,	 	
is	 proteolytically	 cleaved	 and	 thereby	 secreted	 into	 the	 	
extracellular	space	(50),	a	process	called	ectodomain	shed-
ding.	To	 test	 whether	 such	 mechanism	 applies	 to	TL1A,	 	
U-2OS	cells	and	HUVEC	were	transiently	transfected	with	
pcDNA3.1/TL1A.	 Twenty-four	 hours	 after	 transfection,	
cells	were	washed	and	the	medium	was	replaced.	After	incu-
bation	for	an	additional	24	hours,	cell	extract	and	superna-
tants	were	prepared	and	analyzed	by	Western	blot	(Figure	2B	
and	C).	In	cell	extracts,	a	main	protein	species	with	an	appar-
ent	MW	of	36	kDa	was	detected,	along	with	several	bands	of	
lower	MW.	Two	bands	of	about	30	and	25	kDa	were	detected	
in	the	supernatant	of	transfected	cells.	This	observation	im-
plies	that	the	36-kDa	band	in	the	cell	extract	represents	the	
uncleaved	transmembrane	form	of	TL1A,	which	is	converted	
to	smaller	extracellular	fragments.	This	process,	referred	to	
as	ectodomain	shedding,	usually	involves	enzymes	of	the	
ADAM	(A	Disintegrin	And	Metalloprotease)	family	(51),	
and	many	members	of	the	TNF	receptor	family	are	proteo-
lytically	 cleaved	 by	 TACE	 (TNF-a	 converting	 enzyme/
ADAM17).	To	test	whether	ectodomain	shedding	of	TL1A	
involves	ADAM	metalloproteases,	cells	were	treated	with	
TAPI-1,	a	specific	inhibitor	of	ADAM17.	The	shedding	as-
say	was	validated	by	showing	the	inhibition	of	Prion	protein	
(PrP)	shedding,	which	depends	on	ADAM17	(52).	An	11.5	
kDa	fragment	of	PrP	referred	to	as	N1	was	detected	in	the	
supernatant	of	U-2OS	cells	overexpressing	PrP,	and	the	gen-
eration	of	this	fragment	was	successfully	inhibited	by	the	
addition	of	10	mM	TAPI-1	(data	not	shown).
The	amount	of	soluble	fragments	in	the	supernatant	of	
cells	overexpressing	TL1A	was	strongly	reduced	by	the	ad-
dition	of	10	mM	TAPI-1	(Figure	2C),	indicating	that	the	in-
hibition	 of	 ADAMs	 reduces	 the	 constitutive	 release	 of	
soluble	TL1A	in	U-2OS	cells.	It	is	known	that	PMA	can	
stimulate	the	shedding	activity	of	cells	(53)	and	that	ROS	
production	is	involved	in	PMA-induced	ectodomain	shed-
ding	 (54).	To	 address	 the	 question	 if	TL1A	 ectodomain	
shedding	can	also	be	activated	via	this	pathway,	cells	were	
treated	 for	 2	 hours	 with	 PMA	 and	 H2O2,	 respectively.	
Whereas	both	treatments	did	not	induce	visible	differences	
in	cell	size	or	cell	number	(Figure	2D),	we	observed	en-
hanced	TL1A	ectodomain	shedding	when	cells	were	treated	
with	PMA	(Figure	2E)	or	H2O2	(Figure	2F).
Two	major	bands	with	apparent	MW	of	30	and	25	kDa	were	
found	in	the	supernatant	of	cells	expressing	TL1A.	It	is	known	
that	both	secreted	proteins	and	membrane	proteins	(facing	to-
ward	the	extracellular	space)	are	subject	to	glycosylation.	
Accordingly,	the	TL1A	fragments	observed	in	conditioned	
media	may	result	from	differential	glycosylation,	as	was	sug-
gested	by	others	before	(23).	Prediction	of	N-glycosylation	
sites	using	bioinformatics	tools	indicated	two	potential	gly-
cosylation	sites	at	N133	and	N229	of	the	full-length	TL1A	
sequence	(55).	To	test	this	possibility,	supernatant	of	TL1A	
overexpressing	cells	was	treated	with	N-glycosidase	F	to	
remove	N-linked	saccharides,	which	shifted	both	fragments	
toward	lower	MW	(Figure	2G).	As	a	result	of	extended	gly-
cosidase	treatment,	a	third	fragment	of	further	reduced	MW	
was	observed	in	some	experiments,	which	may	result	from	
proteolytic	degradation;	this	was	not	further	investigated.	
The	addition	of	four	additional	enzymes,	which	would	re-
move	possible	O-linked	saccharides,	had	no	significant	im-
pact	on	the	apparent	MW	of	the	TL1A	fragments	(Figure	2G),	
suggesting	that	the	extracellular	soluble	fragments	of	TL1A	
are	N-glycosylated	but	not	O-glycosylated.	There	seems	to	
be	no	differential	posttranslational	modification	of	the	two	
TL1A	fragments,	which	indicates	that	both	fragments	most	
likely	differ	by	their	amino	acid	composition.
Role of TL1A in CEP Senescence
To	investigate	the	regulation	of	TL1A	during	senescence	of	
human	endothelial	cells,	human	CEP	were	isolated	from	pe-
ripheral	blood	of	young	and	old	human	donors.	To	approve	
their	endothelial	identity,	CD31,	an	adhesion	molecule	ex-
pressed	mainly	on	endothelial	cells,	and	von	Willebrand	fac-
tor,	another	endothelial	cell–specific	molecule,	were	stained	
by	indirect	immunofluorescence	and	evaluated	by	fluores-
cence	microscopy.	The	isolated	CEP	were	positive	for	von	
Willebrand	and	CD31,	which	supports	their	endothelial	na-
ture	(data	not	shown).	CEP	isolated	from	a	young	donor	(Y2)	
were	 serially	 passaged	 until	 they	 reached	 senescence,	 as	
monitored	by	positive	staining	for	SA-b-gal.	According	to	the	
established	protocol,	CEP	cultures	are	derived	from	single	or	
very	few	cells,	which	emerged	from	the	selection	procedure,	
selecting	cells	for	growth	in	endothelial	growth	medium	and	
adherence	to	collagen-coated	dishes.	These	colonies	derive	
from	one	single	cell	or	at	best	a	few	cells.	Senescence	experi-
ments	were	started	when	about	a	million	cells	were	available.	
This	means	that	at	the	beginning	of	the	experiments	the	cells	
already	underwent	roughly	18	population	doublings	on	aver-
age.	From	this	point,	cells	could	be	grown	for	another	five	 	
to	six	passages	before	they	reached	senescence.	Senescence	
was	defined	as	the	point,	when	more	than	80%	of	the	cells	MÜCK ET AL. 1172
Figure	3.	 Upregulation	of	tumor	necrosis	factor–like	cytokine	1A	(TL1A)	messenger	RNA	(mRNA)	in	replicative	senescent	circulating	endothelial	progenitor	
cells	(CEP)	as	well	as	in	elderly	donors.	(A)	CEP	of	a	young	donor	(Y2	=	35	years)	were	serially	passaged	until	they	reached	senescence.	mRNA	was	prepared	and	
subjected	to	cDNA	microarray	analysis.	Microarray	results	were	normalized,	and	the	regulation	for	TNFSF15	probe	set	(TL1A)	is	shown.	(B)	In	addition,	CEP	of	
young	(Y1	=	30	years)	and	old	donors	(O1	=	70	years	and	O2	=	79	years)	were	isolated	and	analyzed	by	cDNA	microarray.	(C)	The	mRNA	expression	observed	by	
cDNA	microarray	analysis	was	confirmed	by	real-time-quantitative-PCR	(RTq-PCR)	using	primers	specific	for	the	detection	of	TL1A.	Results	are	shown	as	fold	
change	compared	with	“young”	CEP	regarding	replicative	age	or	donor	age,	respectively.	(D)	CEP	derived	from	three	young	donors	(Y3,	Y4,	and	Y5)	were	transduced	
with	either	control	lentivirus	or	three	lentiviral	knockdown	vectors	targeting	TL1A	(pLKO1,	pLKO99).	RTq-PCR	showing	the	lentiviral	knockdown	of	TL1A	in	CEP	 	
was	performed	8	and	10	days	after	transduction	at	the	indicated	passage	numbers.	Results	are	shown	as	fold	change	compared	with	control.	(E)	Quantification	of	
senescence-associated	b-galactosidase	(SA-b-gal)–positive	cells	after	knockdown	of	TL1A.	CEP	of	young	donors	(Y3,	Y4	and	Y5)	were	fixed	and	stained	for	SA-b-gal	
7	or	9	days	after	transduction.	Phase	contrast	microscopic	pictures	were	taken	at	400×	magnification.	The	percentage	of	SA-b-gal–positive	cells	was	calculated	by	
counting	about	1,500	cells	per	experiment.	(F)	CEP	were	transduced	with	lentiviral	vectors	expressing	green	fluorescent	protein	(GFP)	or	TL1A,	and	cell	extracts	
were	subjected	to	Western	blot	using	GFP	or	TL1A-specific	antibodies,	respectively.	Wild-type	CEP	were	used	as	a	control.	(G)	Six	days	after	transduction,	cells	were	
fixed	and	stained	for	SA-b-gal.	Pictures	are	representative	of	at	least	three	experiments. DIFFERENTIAL ECTODOMAIN SHEDDING OF TL1A 1173
were	positive	for	staining	with	SA-b-gal.	Total	mRNA	was	
isolated	from	CEP	at	early	and	late	passage	and	subjected	to	
cDNA	microarray	analysis	using	Affymetrix	microarray	HG-
U133Plus2.0,	revealing	differential	regulation	of	about	1000	
genes	in	cellular	senescence	(data	not	shown).	TL1A	mRNA	
was	upregulated	ninefold	in	senescent	CEP	(Figure	3A).	To	
investigate	if	regulation	of	TL1A	by	replicative	senescence	is	
also	reflected	in	vivo,	TL1A	expression	levels	of	CEP	iso-
lated	from	two	old	donors	(O1	and	O2)	were	compared	with	
levels	of	young	donor	1	(Y1).	A	4-	to	12-fold	upregulation	 	
of	 TL1A	 in	 CEP	 derived	 from	 old	 donors	 was	 observed	 	
(Figure	3B).	Regulation	of	TL1A	gene	expression	shown	in	
Figure	3B	was	confirmed	by	RTq-PCR	with	TL1A	isoform-
specific	primers	(Figure	3C).
The	amount	of	TL1A	and	the	VEGI-174	isoform	in	se-
nescent	CEP	was	tested	by	isoform-specific	real-time-
quantitative	PCR.	As	a	measure	of	the	template	starting	
amount	in	the	PCR	reaction,	the	threshold	cycle	(ct	value)	
was	analyzed.	The	ct	values	for	TL1A	in	three	senescent	
CEP	cDNA	samples	were	27.3	±	1.1,	suggesting	a	signifi-
cant	amount	of	TL1A	transcript	in	senescent	CEP.	The	same	
cDNA	used	with	isoform-specific	primers	for	VEGI-174	
showed	ct	values	of	34.9	±	1.6,	which	is	at	the	limit	of	de-
tection.	 For	 normalization	 of	 the	 isoform-specific	 RTq-
PCR,	levels	of	b-2	microglobulin	were	quantified	in	parallel,	
showing	a	ct	value	of	19.54	±	0.0	(data	not	shown).	These	
results	confirm	that	the	dominant	isoform	in	senescent	CEP	
is	TL1A.	Detection	of	isoform	VEGI-192	was	not	attempted	
because	it	is	reported	to	be	even	less	abundant	than	VEGI-
174	(23).
To	address	a	potential	contribution	of	TL1A	to	CEP	se-
nescence,	lentiviral	knockdown	of	TL1A	was	performed	in	
CEP	from	three	different	young	donors	with	knockdown	
constructs	 targeting	 two	 different	 regions	 of	 the	 TL1A	
mRNA.	CEP	from	donors	Y3,	Y4,	and	Y5	were	transduced	
with	8	multiplicity	of	infection.	CEP	isolated	from	periph-
eral	blood	generally	reach	senescence	quite	early	because	
of	extensive	proliferation	at	the	beginning	of	the	culture	
(46),	that	is,	in	passage	10–13,	and	CEP	in	passage	7	there-
fore	 represent	 CEP	 that	 are	 already	 near	 senescence.	 	
Figure	 3D	 shows	 the	 efficiency	 of	 the	 two	 knockdown	 	
constructs	to	downregulate	endogenous	TL1A	versus	con-
trol.	TL1A	knockdown	cells	were	stained	for	SA-b-gal	7	
and	9	days	after	transduction,	and	the	amount	of	stained	
cells	was	quantified	(Figure	3E).	For	both	TL1A-specific	
shRNAs,	the	amount	of	SA-b-gal–positive	cells	was	de-
creased	compared	with	control.
The	role	of	TL1A	in	senescence	of	CEP	was	also	studied	
by	lentiviral	overexpression	of	TL1A.	Overexpression	of	
TL1A	was	performed	in	early	passage	cells	from	a	young	
donor	with	green	fluorescent	protein	as	a	control	and	con-
firmed	by	Western	blot	(Figure	3F).	Six	days	after	transduc-
tion,	CEP	were	stained	for	SA-b-gal,	and	the	amount	of	
SA-b-gal–positive	cells	was	quantified	(Figure	3G).	TL1A	
overexpression	increased	the	amount	of	SA-b-gal–positive	
cells	 by	 about	 20%	 compared	 with	 CEP	 overexpressing	
green	fluorescent	protein.
Effects of TL1A Expression in HUVEC
The	ability	of	TL1A	to	influence	the	senescence	response	
in	young	HUVEC	was	tested	by	overexpression.	To	this	end,	
a	lentiviral	system	was	established	to	efficiently	transduce	
primary	cells	with	low	toxicity.	Young	HUVEC	in	passage	7	
were	transduced	with	five	multiplicity	of	infection	of	empty	
vector	 (Mock)	 and	 TL1A	 overexpression	 vector,	 respec-
tively.	Figure	4A	shows	the	overexpression	of	TL1A	7	days	
after	transduction	of	young	HUVEC,	evaluated	by	TL1A-
specific	Western	blot.	Investigating	the	cells	by	phase	con-
trast	microscopy	6	days	after	transduction	revealed	diminished	
cell	numbers	and	an	enlarged	phenotype	of	HUVEC	overex-
pressing	TL1A	compared	with	Mock	(Figure	4B).	Three	days	
after	transduction,	TL1A-transduced	HUVEC	stopped	pro-
liferation	(Figure	4C).	To	investigate	the	amount	of	cells	in	
S	phase,	cells	were	incubated	with	bromodeoxyuridine	for	
1.5	hours	and	stained	for	incorporation.	TL1A	overexpression	
severely	reduced	the	amount	of	cells	in	S	phase	(Figure	4D).	
Annexin	V	staining	of	Mock	and	TL1A-transduced	cells	 	
4	and	6	days	after	transduction	shows	an	increase	in	apop-
tosis	of	TL1A	overexpressing	cells	(Figure	4E).	The	earlier	
observations	are	typical	signs	for	the	induction	of	a	senes-
cent-like	phenotype	in	HUVEC	(56)	by	TL1A	overexpres-
sion.	To	further	confirm	this	effect,	cells	were	stained	for	
SA-b-gal	7	days	after	transduction,	and	staining	was	docu-
mented	by	phase	contrast	microscopy	(Figure	4F).	This	ex-
periment	revealed	a	strong	increase	in	staining	for	SA-b-gal	
in	TL1A	overexpressing	cells.	The	ability	of	endothelial	
cells	to	differentiate	on	Matrigel	to	form	tubes	within	 	
24	hours	is	a	common	assay	for	angiogenesis	(57).	Cells	
were	placed	on	Matrigel	incubated	over	night	and	then	the	
branching	points	per	visual	field	were	assessed.	Figure	4G	
shows	a	diminished	rate	of	tube	formation	of	HUVEC	over-
expressing	TL1A.
Differential Induction of Endothelial Cell Apoptosis by 
TL1A Fragments
When	young	HUVEC	were	incubated	with	conditioned	
medium	from	TL1A	expressing	U-2OS	cells,	we	observed	a	
slight	increase	in	the	rate	of	apoptosis	and	a	reduction	in	the	
number	of	viable	cells	(data	not	shown),	suggesting	a	poten-
tial	contribution	of	extracellular	TL1A	fragments	to	the	pro-
apoptotic	 phenotype	 obtained	 by	 ectopic	 expression	 of	
TL1A	(see	previously,	Figure	4E).	However,	the	detectable	
concentration	of	TL1A	in	conditioned	medium	was	very	
low	 (less	 than	 0.1	 ng/mL;	 data	 not	 shown),	 which	 may	 	
limit	the	efficiency	of	the	conditioned	medium.	The	low	
TL1A	concentration	in	conditioned	media	also	prevented	
our	attempts	to	purify	TL1A	fragments	from	conditioned	
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Figure	4.	 Phenotypic	consequences	of	lentiviral	tumor	necrosis	factor–like	cytokine	1A	(TL1A)	overexpression	in	young	human	umbilical	vein	endothelial	cells	
(HUVEC).	(A)	Lentiviral	overexpression	of	TL1A	was	confirmed	7	days	after	transduction	of	young	HUVEC	in	passage	7	by	Western	blot	using	antibodies	specific	
for	TL1A.	Lentiviral	empty	vector	(Mock)	was	used	as	a	control.	(B)	Six	days	after	transduction,	morphology	of	transduced	cells	was	observed	by	phase	contrast	
microscopy.	(C)	Population	doubling	time	was	assessed	via	CASY	cell	counting.	(D)	Six	days	after	transduction,	the	amount	of	cells	in	S	phase	was	determined	using	
a	bromodeoxyuridine	assay.	4-6-diamidino-2-phenylindole	was	used	to	stain	cell	nuclei.	Pictures	shown	are	representative	of	at	least	three	experiments.	(E)	Four	and	
six	days	after	lentiviral	transduction	of	young	HUVEC	with	either	empty	vector	(Mock)	or	TL1A,	the	cells	were	stained	with	Annexin	V	and	monitored	for	apoptosis	
by	FACS.	(F)	Seven	days	after	lentiviral	transduction	of	HUVEC	with	either	empty	vector	(Mock)	or	TL1A,	cells	were	fixed	and	stained	for	senescence-associated	
b-galactosidase	(SA-b-gal).	Pictures	are	representative	of	at	least	three	experiments.	(G)	Five	days	after	lentiviral	transduction	of	young	HUVEC	with	either	empty	
vector	(Mock)	or	TL1A,	5	×	104	cells	each	were	seeded	on	300	mL	Matrigel	in	a	24-well	plate.	On	the	next	day,	tube	formation	was	documented	by	phase	contrast	
microscopy.	Three	experiments	were	performed	and	representative	pictures	are	shown. DIFFERENTIAL ECTODOMAIN SHEDDING OF TL1A 1175
In	an	alternative	strategy	to	test	the	role	of	extracellular	
TL1A	 fragments,	TL1A	 fragments	 of	 the	 predicted	 size	
were	produced	in	E coli.	Fragments	were	designed	accord-
ing	to	the	already	described	TL1A	fragment	TL1AL72-L251	
(21),	and	a	second	fragment	corresponding	to	the	shorter	
TL1A	 fragment	 obtained	 after	 complete	 deglycosylation	
(Figure	5A).	Taking	into	account,	the	MW	difference	be-
tween	both	fragments,	the	shorter	fragment,	referred	to	as	
TL1AV84-L251,	was	designed	to	start	at	amino	acid	84	of	
TL1A.	Recombinant	TL1A	fragments	were	run	side	by	side	
with	deglycosylated	TL1A	fragments	from	conditioned	me-
dium	and	analyzed	by	Western	blot.	As	predicted,	the	larger	
TL1A	fragment	from	conditioned	media	comigrated	with	
recombinant	TL1AL72-L251	(Figure	5A),	whereas	the	smaller	
Figure	5.	 Identity	and	biologic	activity	of	tumor	necrosis	factor	(TNF)–like	cytokine	1A	(TL1A)	fragments.	(A)	Concentrated	cell	supernatant	of	TL1A	overex-
pressing	U-2OS	cells	was	deglycolysed	with	N-glycosidase	F	and	compared	with	the	molecular	weight	of	Escherichia coli	recombinant	TL1A	fragments	TL1AL72-L251	
and	TL1AV84-L251	by	Western	blot	using	TL1A-specific	antibody.	(B)	Sites	for	ADAM-mediated	cleavage	of	TL1A.	Cleavage	between	alanine71	and	leucine72	(indi-
cated	by	an	arrow)	would	lead	to	the	described	TL1AL72-L251	(21).	The	newly	described	TL1AV84-L251	would	be	cleaved	between	glutamine83	and	valine84.	Putative	
transmembrane	region	is	marked	in	dark	grey.	TNF-homology	domain	is	marked	in	light	grey.	Both	domains	were	predicted	by	the	Human	Protein	Reference	 	
Database.	(C)	About	50,000	young	human	umbilical	vein	endothelial	cells	(HUVEC)	in	passage	7	were	seeded	in	six-wells	treated	with	20	mg	of	TL1AL72-L251	or	
TL1AV84-L251	for	24	or	36	hours	and	subjected	to	Annexin	V	FACS	(left)	and	cell	counting	(right),	respectively.	*p	<	.05	and	**p	<	.01,	phosphate-buffered	saline	
(PBS)	versus	TL1AV84	(Student’s	t	test;	n	=	3).	(D)	TL1A	fragments	induced	interferon	(IFN)-g	production	in	human	peripheral	blood	mononuclear	cells	(PBMC).	
(Left)	Percentage	of	IFN-g-expressing	PBMC.	(Right)	Percentage	of	IFN-g-expressing	natural	killer	cells.	*p	<	.05	and	**p	<	.01,	IL-12+IL-18	versus	L72,	V84	and	
IL-15	(Student’s	t	test;	n	=	3).MÜCK ET AL. 1176
TL1A	fragment	comigrated	with	recombinant	TL1AV84-L251	
(Figure	5A),	suggesting	the	occurrence	of	one	additional	
ADAM	cleavage	site	between	Q83	and	V84	of	full-length	
TL1A.	Both	the	canonical	and	the	newly	identified	cleavage	
site	are	located	between	the	transmembrane	region	of	TL1A	
and	the	TNF-homology	domain	(Figure	5B).
Whereas	we	show	in	this	communication	that	TL1A	is	a	
transmembrane	protein	that	releases	two	soluble	ectodo-
main	fragments	by	shedding	(Figure	2),	it	was	reported	in	
the	 literature	 that	 recombinant	 TL1AL72-L251	 showed	 no	
effect	 on	 HUVEC	 proliferation	 or	 apoptosis	 but	 had	
strong	effects	on	cells	of	the	immune	system	like	PBMCs	
(21,58).	Conversely,	shorter	recombinant	fragments	showed	
proapoptotic	properties	on	endothelial	cells	(59,60).	To	test	
if	the	two	soluble	TL1A	fragments	identified	in	this	com-
munication	have	divergent	biologic	effects	on	HUVEC	and	
PBMCs,	recombinant	fragments	were	incubated	with	HU-
VEC	 and	 PBMC,	 respectively.	 TL1AV84-L251	 but	 not	
TL1AL72-L251	induced	apoptosis	in	HUVEC	after	24	hours	
of	treatment,	as	assessed	by	Annexin	V	FACS	(Figure	5C,	
left)	and	strongly	reduced	cell	viability	after	36	hours	of	
treatment	as	assayed	by	CASY	cell	counting	(Figure	5C,	
right).	In	PBMCs,	TL1AV84-L251	was	more	effective	than	
TL1AL72-L251	to	induce	IFN-g	secretion	after	stimulation	
with	 IL-12/IL-18	 (Figure	 5D,	 left).	 Within	 the	 PBMC	 	
pool,	the	NK	cells	was	the	predominant	population	of	cells	
that	 produced	 IFN-g	 upon	 TL1A	 fragment	 treatment	
(Figure	5D,	right).	TL1AV84-L251	was	just	as	effective	in	in-
ducing	IFN-g	secretion	as	IL-15.
Discussion
In	this	study,	we	clarified	the	role	of	TL1A	and	its	sus-
pected	splice	variants	in	human	endothelial	cells.	We	for-
mally	showed	that	full-length	TL1A	is	inserted	into	the	cell	
membrane	and	provide	new	data	suggesting	that	two	extra-
cellular	TL1A	fragments	with	nonidentical	functions	are	
generated	by	differential	ectodomain	shedding.	We	found	
that	the	expression	of	TL1A	increased	with	donor	age	in	
CEP,	and	upregulation	of	TL1A	was	also	found	with	in	vitro	
senescence	of	CEP.	To	study	the	role	of	TL1A	in	senescence	
and	apoptosis	of	endothelial	cells,	we	established	a	lentivi-
ral	system	to	overexpress	and	knockdown	TL1A	in	HUVEC	
and	CEP	and	found	that	TL1A	induces	cellular	senescence	
in	both	model	systems.	Together,	these	observations	estab-
lish	TL1A	as	a	novel	regulator	of	cellular	senescence	in	 	
human	endothelial	cells.
TL1A/VEGI-251 is the Predominant RNA Species in 
Endothelial Cells
Three	cDNAs	derived	from	the	VEGI/TL1A	gene	have	
been	described,	namely	VEGI-174,	VEGI-192,	and	VEGI-
251,	the	latter	being	also	referred	to	as	TL1A.	These	cDNA	
species	differed	in	their	N-terminal	region	and	therefore	can	
be	distinguished	by	PCR	with	isoform-specific	primer	pairs.	
TL1A	was	found	to	be	quantitatively	by	far	the	main	iso-
form	 in	 both	 HUVEC	 and	 CEP,	 whereas	 levels	 of	 both	
VEGI-174	and	VEGI-192	were	very	low	in	HUVEC,	in	
agreement	with	other	studies	(23),	and	in	CEP.
Initially,	VEGI-174	had	been	described	as	the	principal	
full-length	gene	product	(19),	and	high	amounts	of	VEGI-
174	were	reported	in	placenta	mRNA	(23),	suggesting	that	
it	might	be	an	authentic	form	of	VEGI	RNA.	Indeed,	we	
could	readily	isolate	and	clone	a	VEGI-174	DNA	fragment	
from	a	commercially	available	placenta	mRNA	(data	not	
shown).	However,	the	placenta	mRNA	had	been	isolated	
with	 a	 modified	 guanidinium	 thiocyanate	 method	 (61),	
which	is	known	to	yield	considerable	amounts	of	genomic	
DNA	contamination	(62).	BLASTing	the	putative	mRNA	of	
VEGI-174	 (GenBank	AF039390)	 against	 the	 human	 ge-
nome	revealed	that	the	putative	mRNA	is	coded	by	a	contin-
uous	 genomic	 region	 (data	 not	 shown).	 Therefore,	 it	 is	
highly	likely	that	the	VEGI-174	DNA	clone	derived	from	
genomic	DNA	rather	than	cDNA.
TL1A is a Transmembrane Protein Subjected to 
Differential Ectodomain Shedding by ADAM 
Metalloproteases
The	subcellular	localization	of	the	uncleaved	TL1A	pre-
cursor	protein	was	not	known	before	our	study.	The	hydro-
phobicity	 analysis	 of	 TL1A	 shows	 a	 typical	 N-terminal	
peak	indicating	hydrophobic	amino	acids	that	can	be	in-
serted	 into	 the	 plasma	 membrane	 (data	 not	 shown).	We	
show	here	that	TL1A	localizes	to	the	cell	membrane	and	the	
Golgi	apparatus,	essential	for	secretion	or	for	insertion	into	
the	membrane	(63).	Accordingly,	a	prominent	TL1A	pro-
tein	species	of	36	kDa	was	obtained	in	cell	extracts,	proba-
bly	representing	the	membrane	inserted	uncleaved	TL1A.	
Conflicting	results	were	reported	concerning	the	localiza-
tion	and	mode	of	secretion	of	TL1A.	TL1A	was	predicted	to	
be	secreted	because	the	hydrophobic	N-terminus	was	inter-
preted	as	a	secretion	signal	(23),	whereas	others	used	FACS	
analysis	of	antibody	decorated	cells	to	conclude	that	TL1A	
is	a	transmembrane	protein,	in	line	with	known	properties	
of	other	TNF	ligands	(21,35).	Data	shown	here	clearly	sup-
port	the	latter	explanation	and	identify	TL1A	as	a	trans-
membrane	 protein	 anchored	 into	 the	 plasma	 membrane	
with	its	N-terminus,	a	characteristic	feature	of	type	II	trans-
membrane	proteins.	The	data	shown	here	highlight	the	in-
volvement	of	ADAM	metalloproteases	in	the	proteolytic	
cleavage	of	transmembrane	TL1A	for	the	first	time.
Processing	of	TL1A	into	secreted	protein	fragments	was	
described	 before,	 and	 the	 N-terminal	 amino	 acid	 of	 one	
such	fragment	was	determined	as	L72	(21),	which	was	sub-
sequently	referred	to	as	TLAL72-L251.	TLAL72-L251	was	re-
ported	as	the	only	secreted	form	of	TL1A	and	recombinant	
protein	produced	in	E coli	was	used	to	demonstrate	its	bio-
logic	effects	on	PBMCs	and	T	cells	leading	to	a	proinflam-
matory	response	(21,58).	In	the	current	study,	two	distinct	 DIFFERENTIAL ECTODOMAIN SHEDDING OF TL1A 1177
fragments	of	TL1A	were	obtained	in	the	supernatant	of	U-
2OS	and	HUVEC	after	TL1A	expression,	whereas	other	
TNF	ligands	are	generally	reported	to	release	just	one	dis-
tinct	 fragment.	Two	 potential	 N-glycosylation	 sites	 were	
predicted	at	N133	and	N229	of	TL1A	(55),	raising	the	pos-
sibility	that	altered	glycosylation	patterns	were	responsible	
for	differences	in	the	apparent	MW	of	the	fragments	(23).	
This	possibility	could	be	excluded	by	our	studies	because	
after	removing	all	N-	and	O-bound	saccharides,	two	frag-
ments	with	different	MW	(20	and	25	kDa)	remained.	Be-
cause	the	formation	of	both	fragments	was	inhibited	to	the	
same	extend	by	TAPI-1,	it	seems	that	two	distinct	fragments	
are	produced	from	TL1A	by	differential	ectodomain	shed-
ding.	Data	shown	here	suggest	the	occurrence	of	an	addi-
tional	cleavage	site	for	TL1A	located	between	Q83	and	V84	
of	the	full-length	protein.	Both	cleavage	sites	are	located	
between	the	transmembrane	region	of	TL1A	and	the	TNF-
homology	domain	(Figure	5B)	as	expected.	Data	shown	
here	 support	 the	 novel	 concept	 that	 membrane	 inserted	
TL1A	is	differentially	processed,	presumably	via	ectodo-
main	shedding	at	two	different	cleavage	sites,	resulting	in	
two	soluble	TL1A	fragments.
TL1A: A Novel Regulator of Cellular Senescence in 
Human Endothelial Cells
TL1A	mRNA	was	upregulated	in	human	CEP	from	old	
versus	 young	 human	 volunteers	 (Figure	 3A);	 moreover,	
TL1A	was	also	upregulated	upon	extended	passaging	of	
CEP,	suggesting	a	novel	role	of	TL1A	in	the	senescence	of	
endothelial	cells	in	vitro	and	in	vivo.	Supporting	a	func-
tional	role	of	TL1A	in	CEP	senescence,	we	found	that	de-
pletion	of	TL1A	extended	the	replicative	life	span	of	CEP	
cultures.	 When	 full-length	 TL1A	 was	 overexpressed	 in	
young	HUVEC	or	CEP,	this	led	to	the	enlarged	phenotype	
typical	of	senescent	cells,	strong	staining	for	SA-b-gal,	an	
inhibition	 of	 cell	 proliferation,	 and	 an	 increased	 rate	 of	
apoptosis,	representing	characteristic	features	of	senescent	
endothelial	cells	(56).	However,	CEP	seem	to	be	more	resis-
tant	to	apoptosis	compared	with	HUVEC,	in	line	with	the	
known	increased	sensitivity	of	HUVEC	toward	proapop-
totic	stimuli,	such	as	oxidative	stress	(64).	In	conclusion,	
overexpression	of	full-length	TL1A	in	young	HUVEC	and	
CEP	induced	premature	senescence,	and	senescence	was	
delayed	 in	 CEP	 when	TL1A	 was	 depleted.	These	 novel	
findings	suggest	a	causal	role	of	TL1A	in	senescence	of	 	
endothelial	cells.
The	mechanisms	by	which	TL1A	regulates	endothelial	
cell	senescence	remain	to	be	established.	TL1A	is	known	to	
interact	with	death	receptor	3	(DR3),	and	this	interaction	
can	be	modulated	by	DcR3.	Both	DR3	and	DcR3	are	ex-
pressed	in	HUVEC	and	CEP	(data	not	shown),	suggesting	
that	these	receptors	may	be	involved	in	the	phenotypic	al-
terations	obtained	by	TL1A	overexpression.	Accordingly,	it	
was	reported	that	DcR3,	a	known	decoy	for	TL1A,	induces	
HUVEC	proliferation	(34),	and	effects	of	DcR3	on	endo-
thelial	cell	proliferation	were	conferred	via	blocking	the	
negative	regulatory	role	of	TL1A	(34).	The	authors	sug-
gested	 that	 DcR3	 might	 act	 as	 an	 angiogenic	 factor	 via	
blocking	the	negative	regulator	TL1A.	This	hypothesis	is	
consistent	with	our	finding	that	knockdown	of	TL1A	in	hu-
man	CEP	induces	cell	proliferation.
Biologic Activities of Extracellular TL1A Fragments
According	to	the	literature,	the	fragment	TL1AL72-L251	
has	immunomodulatory	activities.	The	signal	induced	by	
this	fragment	on	T	cells	via	DR3	interactions	results	in	in-
creased	responsiveness	to	IL-2	and	in	the	secretion	of	pro-
inflammatory	 cytokines	 like	 IFN-g	 and	 granulocyte	
macrophage	colony-stimulating	factor	(21).	Furthermore,	
TL1AL72-L251	was	shown	to	synergize	with	IL-12	and	IL-18	
to	enhance	IFN-g	production	in	human	T	cells	and	NK	cells	
(33).	Although	DR3	contains	a	death	domain,	TL1AL72-L251	
did	not	induce	significant	caspase	activation	or	apoptosis	in	
primary	T	cells	(21,65).	Besides	T	cells,	the	fragment	stim-
ulated	monocytes/macrophages	to	secrete	IL-8	via	DR3-
mediated	 nuclear	 factor	 kappa	 B	 activation	 (66).	 The	
secretion	of	proinflammatory	IFN-g	was	stimulated	in	lam-
ina	propria	mononuclear	cells,	indicating	that	TL1A	may	
have	 a	 role	 in	 inflammatory	 bowel	 disease	 (26,29).	The	
TL1A	fragment	also	increased	IL-2	production	in	PBMCs	
(58).	These	 results	 show	 a	 strong	 effect	 of	 recombinant	
TL1AL72-L251	on	cells	of	the	immune	system,	which	results	
in	a	proinflammatory	response.	In	line	with	these	data,	we	
show	here	that	TL1AL72-L251	induced	IFN-g	secretion	in	hu-
man	PBMCs	stimulated	with	IL-12	and	IL-18,	and	most	
probably	NK	cells	are	the	main	source	of	IFN-g	production	
(Figure	5D).
A	major	unresolved	question	in	research	on	TL1A	con-
cerns	the	point	that	TL1A	overexpression	leads	to	antipro-
liferative	 and	 proapoptotic	 effects	 in	 endothelial	 cells	
[(21,23),	this	report],	but	the	underlying	mechanisms	re-
mained	elusive.	Recombinant	TL1AL72-L251	did	not	influ-
ence	proliferation	and	survival	in	HUVEC	(Figure	5C),	as	
was	also	observed	by	others	(58).	In	addition,	TL1AL72-L251	
had	no	significant	antiangiogenic	activity	in	vitro	or	in	vivo	
(21,58).	Whereas,	as	pointed	out	previously,	the	only	so	far	
known	extracellular	fragment	of	TL1A,	TL1AL72-L251,	is	de-
void	of	any	proapoptotic	activity,	our	finding	of	a	second	
shorter	TL1A	fragment,	which	has	proapoptotic	activity,	
can	resolve	this	question.	Novel	data	shown	here	suggest	
that	a	second	soluble	fragment	of	TL1A,	most	probably	
TL1AV84-L251,	 is	 generated	 by	 ectodomain	 shedding	 of	
membrane	bound	TL1A	(Figures	2	and	5A).	In	contrast	to	
TL1AL72-L251,	 the	 novel	 fragment	 induced	 apoptosis	 in	
HUVEC	(Figure	5C).	Indeed,	several	previous	reports	de-
scribed	 that	 artificially	 created	 fragments	 shorter	 than	
TL1AL72-L251	 can	 induce	 apoptosis	 in	 endothelial	 cells.	
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majority	of	studies	focused	on	the	application	of	diverse	ex-
tracellular	fragments	of	TL1A	that	were	produced	as	re-
combinant	proteins	in	E coli.	The	strong	focus	on	research	
with	recombinant	proteins	derived	from	the	TNF	family	is	
explained	by	their	potential	therapeutic	value	for	treating	
cancer	(67).
However,	interpretation	of	these	data	is	hampered	by	use	
of	differential	nomenclature,	as	follows:	the	amino	acid	se-
quences	of	VEGI-174	and	TL1A	overlap	in	the	C-terminal	
part,	starting	at	the	V24	residue	of	VEGI-174.	The	V24	res-
idue	in	VEGI-174	corresponds	to	the	V101	residue	in	full-
length	TL1A	(Figure	6).	Therefore,	for	the	following	section,	
the	 nomenclature	 of	 the	VEGI-174	 fragments	 is	 adapted	 	
to	 TL1A.	 The	 application	 of	 recombinant	 TL1AV101-L251	
(VEGIV24-L174)	led	to	the	time-	and	concentration-dependent	
apoptosis	 of	 endothelial	 cells	 (59,60).	 TL1AV102-L251	
(VEGIV25-L174)	also	markedly	inhibited	the	growth	of	endo-
thelial	 cells	 and	 induced	 apoptosis	 (59).	 Recombinant	
TL1AP106-L251	(VEGIP29-L174)	induced	growth	arrest	in	en-
dothelial	cells,	and	cells	that	had	entered	the	growth	cycle	
underwent	apoptosis	via	the	activation	of	caspase-3	(68).	
TL1AA116-L251	(VEGIA39-L174)	was	only	applied	on	cancer	
cell	lines	where	it	induced	apoptosis.	Interestingly,	the	same	
fragment	induced	proliferation	in	human	diploid	fibroblasts	
(69).	TL1AH121-L251	(VEGIH44-L174)	showed	significant	in-
hibitory	effects	on	growth	of	HUVEC,	and	TL1AK129-L251	
(VEGIK52-L174)	inhibited	angiogenesis	(70).
In	summary,	the	data	shown	here	suggest	that	TL1A	is	a	
transmembrane	protein	that	can	be	processed	into	a	large	
fragment	mainly	involved	in	immunomodulation	(TL1AL72-
L251)	and	to	a	smaller	fragment	(putative	TL1AV84-L251)	that	
is	able	to	induce	growth	arrest	and	apoptosis	in	endothelial	
cells,	however,	has	also	strong	effects	on	immune	cells.	The	
two	 fragments	 are	 probably	 produced	 via	ADAM17/10-	
mediated	alternative	cleavage	of	membrane	inserted	TL1A.	
It	 might	 be	 that	 within	 an	 organismic	 context,	 soluble	
TL1AL72-L251	may	exert	its	effects	mainly	in	a	paracrine	
manner	to	influence	cells	of	the	immune	system,	whereas	
the	TL1AV84-L251	fragment	would	act	in	an	autocrine	way	to	
induce	proliferation	inhibition	and	apoptosis	in	endothelial	
cells.
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